The effect of CYP 3A5 genotypic analysis of donor from cardiac death donation on the individualized administration of Tacrolimus
10.3760/cma.j.issn.0254-1785.2013.05.007
- VernacularTitle:DCD供者CYP3A5基因型对肝移植受者术后他克莫司个体化用药的指导意义
- Author:
Ling LI
;
Qifa YE
;
Yingzi MING
;
Ke CHENG
;
Yanfeng WANG
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Cardiac death donors;
Cytochrome P-450 CYP3B5;
Individualized medications
- From:
Chinese Journal of Organ Transplantation
2013;(5):280-283
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of the genotypic analysis of donor from cardiac death donation on the initial dose of Tac for liver transplant recipients and provide individualized administration for the early use of Tac in liver transplantation patients.Method Thirty recipients with a different genotype of CYP3A5 from cardiac death donors were collected from March 2010 to February 2013.The matched recipients were randomly divided into experiment group and control group.There was an adjustment of initial doses of Tac according to the donors' different CYP3A5 genotypes in experiment group but not in control group.Result In experiment and control groups,the average Tac blood concentrations at the 7th day after operation were (7.47 ± 1.83) and (8.68 ± 5.14) ng/mL,and the percent of recipeints reaching the optimal Tac concentrations was 72.2％ and 38.9％,respectively (P＜0.05).In experiment and control groups,22.2％ and 55.6％ recipients needed adjustments of Tac concentrations respectively (P＜0.05).Conclusion Individualized adjustment of Tac initial doses of recipients according to cardiac death donors' different CYP3A5 genotypes was benefit for reaching optimal concentrations as soon as possible and could decrease the rate of rejection,and reduce the side effects of Tac.
